-
12:55:24 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

CHRS - Coherus Biosciences Inc

09/16/21 6:28 PM
Nasdaq : CHRS
conferencesclinical trial
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in
RHEA-AI
very positive
08/18/21 6:41 PM
Nasdaq : CHRS
clinical trial
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC - - Study to be presented September 13 at IASLC 2021 World Conference on
RHEA-AI
very positive